Biostatistics

生物统计学

• 批准号: 10491172
• 负责人: DONNA S. NEUBERG
• 金额: $ 5.96万
• 依托单位: DANA-FARBER CANCER INST
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-09-01 至 2026-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10491172
• 关键词: Animal Experimentation; Animals; Basic Science; Biological Assay; Biometry; Blinded; Chronic Lymphocytic Leukemia; Clinical; Clinical Data; Clinical Research; Correlative Study; Data; Data Set; Disease; Dissection; Epigenetic Process; Genome; Goals; Laboratory Animals; Laboratory Research; Molecular; Molecular Genetics; Mus; Mutation; Outcome; Patient-Focused Outcomes; Patients; Pharmaceutical Preparations; Proteomics; Reproducibility; Research Personnel; Research Project Grants; Resistance; Resources; Richter' s Syndrome; Sampling; Services; Source; Techniques; Therapeutic Studies; Work; design; experimental study; improved; insight; member; novel; novel therapeutics; personalized therapeutic; phenome; programs; repository; research study; response; single cell analysis; single cell technology; tumor

Project Summary/Abstract The purpose of Core 4 Biostatistics is to provide statistical support to all the Projects in this P01. For the association between clinical outcome and the comprehensive molecular and proteomic dissection of Richter's syndrome (RS), as performed by Project 1, the Core will assemble and curate the clinical data provided by internal and external collaborators and perform all analyses of association between these novel findings and appropriate clinical parameters. This will include working closely with Project to assess in cfDNA any RS-specific alternations that may predict this transformation. For all laboratory and animal studies of Projects 2 and 3, the Core will assure that the design, conduct, and analysis of experiments use robust statistical techniques that are appropriately implemented. For Project 2 this includes the single cell analyses of the tumor-intrinsic and tumor- extrinsic features, as well as the longitudinal assessment of these features. The mice developing RS with combinations of common CLL mutations (generated through this P01) will be assessed for response and resistance to novel therapies and analyzed by this Core. DBP studies are performed through Project 3, and the use of the Core for clinical association will permit Project 3 to remain blinded to clinical outcomes when performing their assays, assuring an unbiased assessment of their predictive ability. Through these aims, this central resource for the Projects will coordinate our insights into the trajectories from CLL to RS and support our ability to identify rational and personalized therapeutic strategies that will offer patients an improved chance of cure.

项目摘要/摘要 核心4生物统计学的目的是为P01中的所有项目提供统计支持。为了 临床结局与里希特的综合分子和蛋白质组学剖析之间的关联 综合征（RS），如项目1所执行的，核心将组装和策划由 内部和外部合作者，并在这些新颖的发现与 适当的临床参数。这将包括与项目在CFDNA中的任何RS特定于CFDNA的紧密合作 可以预测这种转变的交替。对于项目2和3的所有实验室和动物研究， 核心将确保实验的设计，进行和分析使用强大的统计技术 适当实施。对于项目2，这包括肿瘤内和肿瘤的单细胞分析 外在特征以及这些特征的纵向评估。小鼠与 将评估常见CLL突变（通过本P01生成）的组合以进行响应和 对新疗法的抗性，并通过该核心进行分析。 DBP研究是通过项目3进行的， 使用核心进行临床协会将使项目3在临床结果中视而不见 进行测定，确保对他们的预测能力进行公正的评估。通过这些目标， 这些项目的中央资源将协调我们对从CLL到RS的轨迹的见解，并支持我们 能够识别理性和个性化的治疗策略，这些策略将为患者带来改善的机会 治愈。